Inhibitors of BRAF and MEK have shown clinical benefit when used in combination, initially in BRAF V600-mutated melanoma for which the following three associations are approved to date by the FDA: vemurafenib/cobimetinib [34,35], dabrafenib/trametinib [10,36,37], and encorafenib/binimetinib [38,39]. Here, MAP2K7 is linked to melanoma.